Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

Myasthenia Gravis Clinical Trial

Official title:

A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Refractory Myasthenia Gravis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05828225
• Other study ID #: TXB2023006
• Status: Recruiting
• Phase: Phase 1
• Start date: April 30, 2023
• Est. completion date: April 20, 2026

Study information

• Verified date: April 2023
• Source: Zhejiang University
• Contact: He Huang, MD
• Phone: 13605714822
• Email: hehuangyu[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with refractory myasthenia gravis, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: April 20, 2026
• Est. primary completion date: April 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Age =18 and gender unlimited;

• 2. Confirmed as refractory myasthenia gravis with AchR antibody positive and accord one of the following three conditions

1. Repeated electrical stimulation suggests neuromuscular conduction deficits;

2. Tensilon test and neostigmine test positive;

3. The doctor judged that the symptoms of MG improved after treatment with oral cholinease inhibitors;

• 3. Consistent with the clinical classification of MGFA myasthenia gravis IIa-IVb (including IIa,IIb,IIIa, IIIb, IVa,IVb)

• 4. The baseline MG-ADL score =5 and the musculi oculi related score< 50 ;

• 5. Baseline QMG score>11;

• 6. Regular treatment with poor efficacy and/or lack of effective treatment means that there is still recurrence or exacerbation after treatment with conventional hormones, immunosuppressants (such as azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine A, cyclophosphamide, etc.) or rituximab;

• 7. The estimated survival time is more than 12 weeks;

• 8. Women of childbearing age who have negative urine pregnancy test before medication administration and agree to take effective contraceptive measures during the trial period until the last follow-up.

Exclusion Criteria:

• 1. Epilepsy history or other central nervous system disease;

• 2. During the screening visit, the patient's thymectomy was less than 12 months or thymectomy was necessary during the study period or thymic radiation therapy ;

• 3. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythm ia in the past;

• 4. Pregnant (or lactating) women;

• 5. Patients with severe active infections;

• 6. Active infection of hepatitis B virus or hepatitis C virus;

• 7. Systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids);

• 8. Those who have used any gene therapy products before;

• 9. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;

• 10. Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0 mg /dl;

• 11. Those who suffer from other uncontrolled diseases are not suitable to join the study;

• 12. HIV infection;

• 13. Any situation that the researchers believe may increase the risk of patients or interfere with the test results.

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis

Intervention

Drug:
• CD19 CAR-T cells injection
CD19 CAR-T in the Treatment of Refractory Myasthenia Gravis

Locations

Country	Name	City	State
China	The first affiliated hospital of medical college of zhejiang university	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicity (DLT)	Adverse events assessed according to NCI-CTCAE v5.0 criteria	Baseline up to 28 days after CD19 CAR T-cells infusion
Primary	Incidence of treatment-emergent adverse events (TEAEs)	Incidence of treatment-emergent adverse events [Safety and Tolerability]	Up to 90 days after CD19 CAR T-cells infusion
Primary	Maximum tolerable dose	Maximum tolerable dose	From date of initial treatment to Day 28 post CD19 CAR-T infusion.
Secondary	Changes in serum AchR antibody titer	Changes in serum AchR antibody titer	days 7, 14, 21, 28 and 90
Secondary	MG-activities of daily living profile (MG-ADL)	MG-ADL Myasthenia Gravis Daily Activity Scale	Baseline up to 28 days after CD19 CAR T-cells infusion
Secondary	MG-activities of daily living profile (QMG)	Quantitative Score for Myasthenia Gravis	Baseline up to 28 days after CD19 CAR T-cells infusion
Secondary	Myasthenia Gravis Composite Scale (MGC)	Myasthenia Gravis Composite Scale	Baseline up to 28 days after CD19 CAR T-cells infusion
Secondary	MG-QOL15 scale	MG-QOL15 Quality of Life Scale for Myasthenia Gravis (15 items)	Baseline up to 28 days after CD19 CAR T-cells infusion